Kornimate/medical-research-clean huggingface dataset:
the use of dendritic cell/tumor hybridomas as a novel tumor vaccine in patients with advance melanoma

Conditions: Metastatic Melanoma

Summary: this study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.

to assess the toxicity associated with vaccination of melanoma patients with dendritic cell (dc)/tumor fusions. to determine if cellular and humoral immunity can be induced by serial vaccination with dc/tumor fusions cells. to determine if vaccination dc/tumor fusions results in a tumor response.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnoses of disseminated melanoma, with measurable and clearly progressive metastatic involevment * patients must be at least 18 years old * patients must have ecog performance status 0-1 with greater than 9 week life expectancy * those patients with the following accessible tumor will be eligible: soft tissue, bone marrow or visceral lesions; skin or superficial soft tissue, or lymph nodes amenable to resection under local anesthesia; patients who require surgical procedures that are not considered significantly invasive but may require general anesthesia, such as thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be eligible; malignant ascites or pleural effusion; patients requiring major surgical intervention will be considered ineligible. patients scheduled to undergo tumor resection for independent diagnostic or therapeutic indications may have tumor collected for the purposes of this study. * labs: wbc \>_ 2.0 x 10x3/ul, bilirubin \<_2.0 mg/dl, creatine \<_ 2.0mg/dl * women of childbearing age must have a negative pregnancy test and adequate contraception method(s) must be documented * all patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines exclusion criteria: * patients must not have received other immunotherapy treatment in the past four weeks prior to study entry * patients must not have received chemotherapy for three weeks prior to the first vaccination * patients must be without evidence of active cns disease * patients must not have clinically significant autoimmune disease * patients must be hiv negative * patients must not have serious intercurrent illness such as infection requiring iv antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure * patients requiring corticosteroids for either melanoma related or co-morbid illness

Keywords: melanoma
experimental study to determine the effects of human refluxate on macrophage phenotype and its correlation with gerd

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: this study is proposed to evaluate the role of motoric dysfunctions and type of refluxate in gerd patients, analyzed the blood monocyte/macrophage phenotypes of gastroesophageal reflux diseases (gerd) patients.

patients with non-erosive gastroesophageal reflux disease (nerd), erosive esophagitis (ee) and barrett esophagus (be) were enrolled. we investigated blood monocyte/macrophage phenotype in patients with different forms of gerd. we analysed of macrophages phenotype by cd25, cd80, cd163, cd206 expression for m2 macrophages. all patients underwent upper gastrointestinal endoscopy with esophagus biopsy. gerd patients underwent esophageal high-resolution manometry (hrm) with a 22-channel water-perfused catheter and solar gi system (medical measurements systems, enschede, the netherlands) and 24-hour impedance and ph monitoring using the ohmega ambulatory impedance ph recorder (medical measurements systems).

Eligibility criteria:
inclusion criteria: clinical (patients) part 1. signed informed consent 2. gender: male or female 3. age: 18-65 years of age 3. clinically and/or endoscopically confirmed diagnosis of gerd exclusion criteria: clinical: (patient) 1. current treatment with proton pump inhibitors and/or histamine-2 receptor antagonists. these treatments should have been stopped at least 1 week prior to study inclusion. 2. female patients who are pregnant, planning to become pregnant or lactating 3. any acute diseases or conditions, exacerbations of concomitant chronic diseases (including but not limited to inflammatory bowel disease (ibd), ulcer disease etc.) at study start/inclusion and/or which are not resolved 14 days prior to study-enrolment. 4. participation in a clinical trial in the past 3 months 5. any condition which, in the opinion of investigator, makes the patient unsuitable for participation in the study

Keywords: gerd barrett's esophagus macrophage fssg questionnaire
efficacy and safety of ultrasound hyperthermia combined with chemotherapy on oral and maxillofacial-head and neck cancer

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to determine whether ultrasound hyperthermia is effective and safe in the treatment of oral and maxillofacial-head and neck cancer.

as a non-invasive treatment, ultrasound hyperthermia has received increasing interest for the treatment of cancer.many studies have shown that therapeutic ultrasound is safe and effective. eligible patients were randomly assigned by using permutated blocks designed for each site to receive either ultrasound hyperthermia combined with chemotherapy (arm a) or chemotherapy alone(arm b).chemotherapy will be conducted as follows. for squamous cell carcinoma of head and neck,it will be administrated with docetaxel(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt), cisplatin(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt) and fluorouracil(at a dose of 75 mg per square meter of body-surface area and intravenous infused last 5 days) . for other types of cancer,the treatments will be administrated in accord with the guideline.in addition,ultrasound hyperthermia will be conducted 5 times(day 1rt,3rd,5th,7th,9th) in arm a. patients in arm b will receive chemotherapy only. one cycle comprises a period of 3 weeks (21 days).all patients will receive 2 cycles in both arms. all the patients eligible for the operation will take surgery. after treatment，some patients with advanced unresectable cancer may be down-staged from stage iv, and will regain the opportunity of operation.

Eligibility criteria:
inclusion criteria: * joined the study voluntary and signed informed consent form * age 18-75，both genders. * had histologically or cytologically confirmed advanced squamous cell carcinoma of the head and neck * at least one lesions can be measured,conventional measurements ≥2cm, computed tomography(ct) examination ≥1cm . * eastern cooperative oncology group(ecog) performance scale 0-2. * life expectancy of more than 6 months. * use of an effective contraceptive method for women when there is a risk of pregnancy during the study. * haemoglobin≥90g/l ,white blood cell(wbc) ≥3×10\^9/l * hepatic function:alat、asat\< 2.5 x uln, tbil\< 1.5 x uln * renal function: creatinine \< 1.5 x uln exclusion criteria: * participation in other interventional clinical trials within 1 month * previous received other drug or operative treatment within 6 month * pregnant or breast-feeding women * history of serious allergic or allergy * patients with the history of serious lung or head disease * local skin ulceration
establishing a covid-19 prospective cohort for identification of secondary hlh

Conditions: COVID

Summary: sars-cov2 has become a pandemic disease putting an enormous burden on health care systems around the world. a considerable amount of patients require intensive care treatment for covid-19 associated pneumonia. at this point there is no specific treatment, apart from supportive intensive care treatment protocols for severe covid-19 disease.the latest reports describe massive hyperinflammation in some of the severe covid-19 patients, which is not a typical finding in virus associated pneumonia. the h-score and the modified hlh 2004 score offer diagnostic tools, that help establishing the diagnosis of hlh. even more important is the expert clinical judgment to establish the diagnosis of shlh.

sars-cov2 has become a pandemic disease putting an enormous burden on health care systems around the world. the course of disease is relatively mild in most of the patients, but there is a considerable amount of patients that require intensive care treatment for covid-19 associated pneumonia. at this point there is no specific treatment, apart from supportive intensive care treatment protocols for severe covid-19 disease.the latest reports describe massive hyperinflammation in some of the severe covid-19 patients. the h-score and the modified hlh 2004 score offer diagnostic tools, that helps establishing the diagnosis of hlh. moreover expert clinical judgment is key to establish a diagnosis of shlh. still, so far no systematic analysis has been carried out answering the question as to whether or not these patients suffer from secondary hlh and could potentially benefit from immunomodulatory drugs.

Eligibility criteria:
inclusion criteria: * age \> 17a * diagnosis of sars cov 2 by pcr testing * hospitalized due to clinical severity of the disease * written and informed consent or consent of the family * gfr\<30 is not an exclusion criterion exclusion criteria: * not fulfilling the inclusion criteria * missing written and informed consent

Keywords: mas hlh covid
prophylactic trimethoprim/sulfamethoxazole to prevent severe infections in patients with lupus erythematous

Conditions: Lupus Erythematosus, Systemic

Summary: the purpose of this study is to determine whether trimethoprim/sulfamethoxazole is effective in preventing serious infectious complications (those that require hospitalization or lead to death) in patients with lupus erythematosus that receive intermediate or high dose steroids.


Eligibility criteria:
inclusion criteria: * systemic lupus erythematosus according to the american college of rheumatology criteria * on a daily dose of prednisone of ≥ 15 mg/d or equivalent, and that are expected to remain on the this dose for at least 1 month. * have signed an informed consent exclusion criteria: * absolute contraindication to receive tmp-smx (known allergy to tmp-smx or sulfa drugs; tmp-smx induced thrombocytopenia) * received tmp-smx treatment in the previous month * creatinine clearance \<30ml/min/m2 * chronic viral infection (hepatitis c virus, hepatitis b virus, human immunodeficiency virus) * malignant neoplasm, except for skin neoplasm * primary immune deficiencies * solid organ or hematopoietic stem cell transplant recipients * pregnancy or breastfeeding * current active infection, except mild active infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. tinea). * uncontrolled chronic infection (e.g. tuberculosis- intensive phase treatment), except mild active chronic infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. onychomycosis). * controlled chronic infection, that needs to be treated or prevented with tmp-smx. * absolute neutrophil count \< 750/mm3, platelets \<30x10\^9/l, o hemoglobin \<7 g/dl * patients receiving methotrexate * patients participating in another research study that to the judgement of the principal investigator could jeopardize the safety or efficacy of the study drug.

Keywords: trimethoprim, sulfamethoxazole drug combination infection prophylaxis
a clinical study of 6mw3211 injection in the treatment of advanced malignant neoplasm

Conditions: Advanced Malignant Neoplasm

Summary: this study is a single arm, non-randomized, open label, multiple doses phase i/ii international, multicenter clinical trial to evaluate safety, tolerability, pk/pd, immunogenicity and preliminary efficacy in subjects with advanced malignant neoplasm. the study is consisted of two stages: dose escalation and clinical expansion. only phase i has been submitted to us fda,and the protocol number is still the same as 6mw3211-2021-cp101.the us title is : a phase 1, first-in-human (fih), multicenter, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of 6mw3211 in patients with advanced malignancies .

six cohorts are included in dose escalation stage, at doses of 0.3\~45 mg/kg, respectively. safety, tolerability, and dose-limiting toxicity (dlt) are assessed during the first 3 weeks (21 days) after initial administration. then, the intended dosing frequency is every 2 weeks (q2w), iv. from the first study drug administration, some dosing cycles will be observed for phase i, initial tumor efficacy assessments will be performed at week 7, after that tumor efficacy assessment will be carry out for every 6 weeks.

Eligibility criteria:
inclusion criteria: * 1. men or women, age ≥18. * 2.subjects with advanced malignancy histopathologically and/or cytologically, with at least one evaluable tumor lesion. * 3.ecog ps is 0 or 1. * 4.survival expectation of at least 3 months. * 5.adequate organs and hematopoietic functions * 6.voluntarily signing of informed consent exclusion criteria: * 1.subjects with brain metastases of clinically active central nervous system (cns). * 2.subjects that require to take anticoagulants and/or aspirin. * 3.blood transfusion within 2 weeks prior to the first administration of study treatment. * 4.inadequately controlled body cavity effusions. * 5.subjects with active, or have a history and possible recurrence of autoimmune diseases . * 6.have uncontrolled systemic diseases. * 7.subjects who had received anticancer therapy or radiotherapy within 4 weeks or 5 half-lives (whichever is shorter) before enrollment. * 8.subjects are known to have previously experienced severe allergic reactions to large molecular protein formulations/monoclonal antibodies. * 9.pregnant or lactating women.
imaging techniques to monitor photosensitizer and so2 levels during photodynamic therapy of actinic keratoses

Conditions: Actinic Keratoses

Summary: the purpose of the study is to test a new video device for actinic keratoses. the device takes images of your skin lesions during the treatment, to learn whether this device can predict how well the treatment is working.

this intervention is designed to help establish what the optimal conditions are for treating actinic keratoses with photodynamic therapy (pdt). the primary outcome of this study is to determine whether the rate of singlet oxygen (so2) production and/or the initial intralesional photosensitize (ppix) levels, can predict the clinical responsiveness of ak lesions to pdt. participants will receive standard red light pdt treatment, except that lesions will be carefully counted beforehand. during the window of red light illumination, photos and a video of one area of skin will be taken to allow us to monitor the progress of the treatment. any remaining lesions will be counted upon follow-up.

Eligibility criteria:
inclusion criteria: * participants who have at least 10 actinic keratoses lesions on the arms of legs, and with two ak lesions close enough to be seen together within a selected region of interest (roi) * participants must be able to understand and are willing to sign a written informed consent document exclusion criteria: * female participants cannot be or become pregnant, nor can be nursing while on this study * using any topical treatment on their aks; must stop at least one month prior * currently undergoing treatment for other cancers with medical or radiation therapy * patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material * patients with history of a photosensitivity disease, such as porphyria cutanea tarda

Keywords: actinic keratoses red light photodynamic therapy protoporphyrin ix
nutritional intakes in burn patients treated as outpatients

Conditions: Burns; Nutritional Deficiency

Summary: nutrition is a key component of burn care. the primary goal of nutrition is to provide adequate supply in macro and micronutrients that are necessary to maintain organ function but also to wound healing, infection control and muscle preservation. studies about nutrition and burn care are mainly focused on severe burn patients. there is a few or no data regarding nutrition in minor burns. those patients rarely receive a multidisciplinary approach, at least in belgium. the present study aimed to describe the nutritional condition of less severe burn patients treated as outpatients in a belgian burn center. the ultimate goal was to determine whether this population needs specific dietetics follow-up or not.


Eligibility criteria:
inclusion criteria: * burn treated exclusively in an outpatient clinic exclusion criteria: * not french speaking * psychiatric disorders * patient refusal
study of 111in-dac as an medical imaging agent for lung cancer and brain cancer consistent with metastatic lung cancer

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms; Metastases, Neoplasm

Summary: the purpose of this study is to investigate the safety and imaging ability of 111in-dac when used with planar and spect imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.


Eligibility criteria:
inclusion criteria patients will be eligible for the study if they: * are male or non-pregnant, non-lactating females 18 years of age or older (must agree to use an appropriate and effective method of birth control during the study and for 2 weeks after study) * have an ecog performance status of zero or one * are being evaluated for known or suspected non-small-cell lung cancer (nsclc), or known brain lesions consistent with metastatic lung cancer * (for nsclc patients)have been previously scheduled for biopsy or surgical excision of the suspected nsclc, or have a pathological diagnosis of lung cancer within 2 months of enrollment but have received no previous treatment * (for brain cancer patients) have clinical signs and symptoms consistent with a primary nsclc with histological or cytopathological confirmation. patients cannot have received previous treatment with radiation to the brain. * have signed an informed consent form exclusion criteria patients will not be eligible for this study if they: * have a history or suspicion of significant allergic reaction or anaphylaxis to any of the 111in-dac components * have a clinically unstable medical condition or opportunistic infection, a life-threatening disease state, impaired renal or hepatic function or are immunosuppressed * are taking or have taken part in any investigational study within 30 days of start of study * have received an indium agent within 30 days of start of study * are not able to remain immobile during scanning time * have taken drugs that may damage the kidneys within 2 weeks of start of study * have abnormal laboratory test results: hemoglobin\ 1.5mg/100ml, alkaline phosphatase 2x the upper limit of normal * have undergone an excisional and/or needle localization biopsy within 4 days prior to study drug administration * have undergone a pet scan within 7 days prior to study drug administration * have any active or previously treated second malignancy except carcinoma in situ of the uterine cervix or non-melanoma skin cancer

Keywords: lung cancer metastatic brain cancer
umbilical cord blood transplantation as treatment of adult patients with hematologic disorders

Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome

Summary: to determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/mmf as graft-versus-host disease prophylaxis.


Eligibility criteria:
inclusion criteria: patients must have a histologically confirmed diagnosis at the vancouver general hospital or the bcca-vancouver. eligible patients will have one of the following underlying diseases: * high risk acute lymphoblastic leukemia (all) in first complete remission, with high risk being defined by the presence of t(4;11), t(9;22) or t(1;19) or patients presenting with extreme hyperleukocytosis (wbc \>100x109/l) or failure to achieve a complete remission after standard induction therapy. * acute myeloid leukemia (aml) in first complete remission with high risk cytogenetics or failure to achieve complete remission after standard induction therapy. all or aml in second or subsequent remission * myelofibrosis with myeloid metaplasia. * chronic myeloid leukemia in chronic (failed interferon and/or gleevec) or accelerated phase. * myelodysplastic syndrome with ipss risk category \>int-1 * aplastic anemia * non-hodgkin's lymphoma, chronic lymphocytic leukemia or hodgkin's disease in relapse or second or subsequent remission. * multiple myeloma * no active central nervous system (cns) disease. * no 9/10 or better hla antigen matched related donor or vud available. * the patient's condition precludes waiting to search and find a vud in the unrelated donor registries * acceptance of standard blood product support * adequate organ function as defined by current leukemia/bmt program of bc standards (appendix 10.1) * karnofsky performance status ≥ 80 (appendix 10.2) exclusion criteria: * active infection * pregnancy * significant psychiatric disorder * progressive disease

Keywords: unrelated umbilical cord blood transplant multiple cord blood